The Archive · A Source

Janssen Announces U.S. FDA Approval of SPRAVATO® to Treat Depressive Symptoms in Adults with MDD with Acute Suicidal Ideation or Behavior

Johnson & Johnson August 3, 2020 www.jnj.com/media-center/press-releases/janssen-announces-u-s-fda-approval-of-spravato-esketamine-ciii-nasal-spray-to-treat-depressive-symptoms-in-adults-with-major-depressive-disorder-with-acute-suicidal-ideation-or-behavior